Buy now: Price is sitting near the pivot/support area (~5.35) after a dilution-driven selloff, while the broader trend signals remain bullish (stacked moving averages) and Street targets imply large upside.
Sentiment check: Options positioning is notably call-heavy (low put/call ratios) and volume is elevated, consistent with traders leaning bullish despite high volatility.
Event-driven view: The direct offering was a near-term negative shock, but it also funds the Phase 3 path for pemvidutide—supportive for a rebound-style trade.
Trend: Bullish moving-average stack (SMA_5 > SMA_20 > SMA_200) suggests the primary trend remains up despite the recent dip.
Momentum: MACD histogram is positive (0.0954) but contracting, implying upside momentum is still positive but weakening short-term.
RSI: RSI(6) ~58.3 = neutral-to-slightly-bullish; not overbought.
Key levels: Pivot/support ~5.349 (price ~5.40 is just above it); downside supports S1 ~4.49 then S2 ~3.959. Upside resistance R1 ~6.209 then R2 ~6.74.
Near-term bias (pattern-based): Model indicates modest positive drift over 1W/1M (+2.84% / +3.74%) with mixed next-day odds.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning: Open interest is heavily call-skewed (Call OI 189,370 vs Put OI 44,976; OI put/call 0.24) → bullish positioning.
Flow today: Put/call volume ratio 0.51 with total volume 14,213; activity is very elevated vs 30D average (205.6%) → strong, sentiment-revealing participation.
Volatility: IV30 ~153.7% vs historical vol ~51.1%; IV percentile 78 → options are pricing large moves; sentiment is bullish but the market expects big swings.
Short-term IV trend: 5D/10D IV averages (176.6/182.3) above current IV30 suggests IV has been elevated and may be cooling slightly.
Technical Summary
Sell
5
Buy
6
Positive Catalysts
supports bullish narrative.
Neutral/Negative Catalysts
Dilution overhang: The 17M-share direct offering is inherently dilutive and can cap near-term rallies until the market digests new supply.
Biotech catalyst risk: The stock remains heavily event/clinical-outcome driven; price can gap on trial/program updates.
No supportive positioning signal from smart-money trackers: Hedge funds and insiders are described as neutral (no notable recent accumulation trend).
Financial Performance
Latest quarter: 2025/Q3
Revenue: ~$5,000 (effectively flat; 0.00% YoY) — still pre-commercial profile.
Profitability: Net income -$19.014M (worse by 16.77% YoY) — losses widened.
Takeaway: Financials reflect a development-stage biotech (no meaningful revenue yet); valuation and price action will be dominated by financing + clinical timeline rather than operating leverage.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
2026-01-27 Barclays: Initiated Overweight, $20 PT (very bullish upside framing; positive view on biotech setup into 2026).
Wall Street pros: High upside targets vs ~$5.40 price; constructive sector view; pemvidutide clinical path seen as value-driving.
Wall Street cons: Targets depend on clinical execution; dilution/financing cycles can continue to pressure near-term price even with positive ratings.
Influential / political trading: No recent congress trading data available; no notable politician/influencer buy/sell information provided.
Wall Street analysts forecast ALT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALT is 13 USD with a low forecast of 12 USD and a high forecast of 14 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast ALT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALT is 13 USD with a low forecast of 12 USD and a high forecast of 14 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.920
Low
12
Averages
13
High
14
Current: 4.920
Low
12
Averages
13
High
14
Barclays
NULL -> Overweight
initiated
$20
AI Analysis
2026-01-27
Reason
Barclays
Price Target
$20
AI Analysis
2026-01-27
initiated
NULL -> Overweight
Reason
Barclays initiated coverage of Altimmune with an Overweight rating and $20 price target.
Barclays
NULL -> Overweight
initiated
$20
2026-01-27
Reason
Barclays
Price Target
$20
2026-01-27
initiated
NULL -> Overweight
Reason
Barclays initiated coverage of Altimmune with an Overweight rating and $20 price target. Barclays initiated coverage of 12 biotech stocks and assumed coverage of 11 with a positive view of the industry. The analyst likes the setup for the group in 2026. Many biotech stocks remain undervalued, the analyst tells investors in a research note. The firm expects continued mergers and acquisitions, "strong" underlying fundamentals, and less of a focus on drug pricing to act as "significant tailwinds."
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ALT
